

1) Status of the notification

Final

2) Issuer

Name CELYAD ONCOLOGY
Identification number 0891-118-115

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A parent undertaking or a controlling person

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Fortress Investment Group LLC	1345 Avenue of the Americas, New York, NY 10105, United States
CFIP CLYD LLC	1345 Avenue of the Americas, New York, NY 10105, United States
CFIP CLYD (UK) Limited	7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

04/09/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

25

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

28'893'101

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Fortress Investment Group LLC	0	0	0	0.00%	0.00%
CFIP CLYD LLC	6'500'000	0	0	0.00%	0.00%
CFIP CLYD (UK) Limited	0	7'954'808	0	27.53%	0.00%



Subtotal	6'500'000	7'954'808		27.53%	
TOTAL		7'954'808	0	27.53%	0.00%



Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
					0	0.00%	
TOTAL					0	0.00%	

 **The totals** will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	7'954'808	27.53%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

.CFIP CLYD (UK) Limited ("CFIP UK"), a United Kingdom limited liability company and a wholly-owned subsidiary of CFIP, directly holds 7,954,808 Ordinary Shares.
 .CFIP CLYD LLC, a Delaware limited liability company ("CFIP"), is the parent of CFIP UK.
 .EIP II UB Investments LP, a Delaware limited partnership ("EIP II"), holds 50% of the membership interests in CFIP.
 .EIP Fund II GP LLC, a Delaware limited liability company ("EIP II GP"), is the general partner of EIP II.
 .Hybrid GP Holdings LLC, a Delaware limited liability company ("Hybrid GP"), is the parent of EIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
 .FIG LLC, a Delaware limited liability company ("FIG LLC"), indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
 .Fortress Operating Entity I LP, a Delaware limited partnership ("FOE I"), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
 .EIG Corp., a Delaware corporation ("EIG Corp."), is the general partner of FOE I.
 .Fortress Investment Group LLC, a Delaware limited liability company ("Fortress"), is the sole owner of EIG Corp and has no controlling shareholder.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of

13) Additional information

The transparency notification covers the following transactions:
 (i) sale of 6,500,000 shares of Celyad Oncology from CFIP CLYD LLC to CFIP CLYD (UK) Limited on 30 August 2023 within the scope of an intragroup share transfer; and
 (ii) subscription to 1,454,808 newly issued shares of Celyad Oncology by CFIP CLYD (UK) Limited on 4 September 2023.
 After both transactions, CFIP CLYD (UK) Limited will hold 7,954,808 shares of Celyad Oncology.

Done at
 On (DD/MM/YYYY)
 Name & capacity

Signature 

For security reasons, the unsigned form in **xlsx** format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.
 In addition, a signed copy in **PDF** format should also be transmitted.

Persons subject to the notification requirement

<i>Name</i>	<i>Adress</i>	<i>Phone number</i>	<i>E-mail</i>	<i>Contact person for legal persons</i>
Fortress Investment Group LLC	1345 Avenue of the Americas, New York, NY 10105, United States	N.A.	clipuma@fortress.com	Christopher LiPuma
CFIP CLYD LLC	1345 Avenue of the Americas, New York, NY 10105, United States	N.A.	clipuma@fortress.com	Christopher LiPuma
CFIP CLYD (UK) Limited	7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom	N.A.	clipuma@fortress.com	Christopher LiPuma

Mandatory

<i>Name</i>	<i>Adress</i>	<i>Phone number</i>	<i>E-mail</i>	<i>Contact person for legal persons</i>
Liedekerke Wolters Waelbroeck	Boulevard de l'Empereur 3, 1000 Brussels, Belgium	+3225511515	w.dedecker@liedekerke.com	Wim Dedecker

Invoicing data

<i>Name</i>	<i>Adress</i>	<i>Phone number</i>	<i>E-mail</i>	<i>Contact person for legal persons</i>
Fortress Investment Group LLC	1345 Avenue of the Americas, New York, NY 10105, United States	[Fortress to confirm]	clipuma@fortress.com	Christopher LiPuma

The personal data which you have provided to the FSMA via this form will be processed by the FSMA as set out in its [Privacy Policy](#).